Systemic lupus erythematosus patients face a greater risk of developing cancer and hematologic malignancies, states recent research.
People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to the research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.
Systemic lupus erythematosus, also called SLE or lupus, is a chronic inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system, and/or other organs of the body. The most common symptoms include skin rashes and arthritis, ofte, n accompanied by fatigue and fever. Lupus occurs mostly in women, typically developing in individuals in their twenties and thirties - prime child-bearing age.
Some studies have shown a link between lupus and cancer risk, and researchers recently aimed to make more precise estimations of this risk. They observed 13,492 people with lupus from 24 medical centers for an average of nine years, for a total of 118,359 patient-years (number of patients multiplied by number of years of observation), and compared these participants to people without lupus.
During the course of this study, 632 cases of cancer were noted, and the data concerning hematological cancers-cancers that affect the bone, blood and lymph nodes-was the most striking: researchers found that people with lupus were 3.2 times more likely to develop lymphomas than the general population and 3.4 times more likely to develop non-Hodgkin''s lymphoma, specifically. They also found that people with lupus were 1.7 times greater risk of developing leukemia.